{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:11:24Z","timestamp":1783635084879,"version":"3.55.0"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2003,6,17]],"date-time":"2003-06-17T00:00:00Z","timestamp":1055808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2003,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p><jats:sup>131<\/jats:sup>I\u2010Metaiodobenzylguanidine (<jats:sup>131<\/jats:sup>I\u2010MIBG) can be used systemically to treat malignant pheochromocytoma. To improve outcome, the authors used higher levels of activity of <jats:sup>131<\/jats:sup>I\u2010MIBG than previously reported. The authors reported the response rates and toxicity levels in patients with malignant pheochromocytoma or paraganglioma who were treated with high\u2010dose <jats:sup>131<\/jats:sup>I\u2010MIBG.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Following debulking surgery and stem cell harvest, 12 patients with malignant pheochromocytoma or paraganglioma were treated with <jats:sup>131<\/jats:sup>I\u2010MIBG. Five had received previous external beam radiation and\/or chemotherapy. The median single treatment dose was 800 mCi (37 gigabecquerels; range, 386\u2013866 mCi) or 11.5 mCi\/kg (range, 5.6\u201318.3 mCi\/kg). The median cumulative dose was 1015 mCi (range, 386\u20131690 mCi).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Three patients had a complete response, two of whom had soft tissue and skeletal metastases. Their median follow\u2010up was 45 months (range, 23\u2013101 months). Seven patients had a partial response (PR), with a median follow\u2010up 43 months (range, 6\u201347 months). Two patients without a response died with progressive disease (PD) and 2 patients with an initial PR died of PD at 13 and 11 months, respectively. Grade 3 thrombocytopenia occurred after 79% (15 of 19) of treatments had been administered. Grade 3 and 4 neutropenia followed 53% (10 of 19) and 19% (4 of 19) of treatments, respectively. One patient required stem cell infusion, and one developed primary ovarian failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The single and cumulative doses of <jats:sup>131<\/jats:sup>I\u2010MIBG were approximately 2\u20133.5 times higher than those used at other centers. Unlike previous reports, two patients with both skeletal and soft tissue metastases had a complete response. Hematologic toxicity was significant but tolerable. High\u2010dose <jats:sup>131<\/jats:sup>I\u2010MIBG may lead to long\u2010term survival in patients with malignant pheochromocytoma. Cancer 2003;98:239\u201348. \u00a9 2003 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.11518<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.11518","type":"journal-article","created":{"date-parts":[[2003,7,14]],"date-time":"2003-07-14T13:08:11Z","timestamp":1058188091000},"page":"239-248","source":"Crossref","is-referenced-by-count":131,"title":["High\u2010dose <sup>131<\/sup>I\u2010metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma"],"prefix":"10.1002","volume":"98","author":[{"given":"Brian","family":"Rose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine K.","family":"Matthay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Huberty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Klencke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,7,2]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1410619"},{"key":"e_1_2_6_3_2","first-page":"695","article-title":"Phaeochromocytoma in Northern Ireland: a 21 year review","volume":"162","author":"Beatty O","year":"1996","journal-title":"Eur J Surg."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)57951-3"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198107023050103"},{"key":"e_1_2_6_6_2","first-page":"197","article-title":"Radiopharmaceutical treatment of malignant pheochromocytoma","volume":"24","author":"Sisson J","year":"1984","journal-title":"J Nucl Med."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03348026"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.229"},{"key":"e_1_2_6_9_2","first-page":"221","article-title":"Normotensive pheochromocytoma, pharmacologic, paraneoplastic and anesthetic complications","volume":"139","author":"Kirby BD","year":"1983","journal-title":"West J Med."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000023277"},{"key":"e_1_2_6_11_2","unstructured":"RoseB MatthayK PriceD et al.High dose 131\u2010I\u2010labeled metaiodobenzylguanidine (MIBG) for the treatment of metastatic pheochromocytoma and paraganglioma[abstract]. 82nd Annual Meeting of the Endocrine Society; Toronto Ontario Canada; June 21\u201324 2000."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2001.118373"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00317a017"},{"key":"e_1_2_6_14_2","unstructured":"HubertyJ PriceD.Trace element enhancement of131I\u2010MIBG therapy exchange yields. 40th Annual Meeting of the Society of Nuclear Medicine; Toronto Ontario Canada; June 8\u201311 1993."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345808"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-197405000-00029"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004020100305"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-109-4-267"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951015)76:8<1476::AID-CNCR2820760827>3.0.CO;2-9"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800051013"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000023190"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.38.433"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01309.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-72-2-455"},{"key":"e_1_2_6_25_2","first-page":"993","article-title":"Chromogranin A assay and 131I\u2010MIBG scintigraphy for diagnosis and follow\u2010up of pheochromocytoma","volume":"42","author":"D'Herbomez M","year":"2001","journal-title":"J Nucl Med."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.36.6.1045"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(18)30319-0"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.77.5.1423"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050400"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6694223"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0969-8043(93)90179-E"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.11518","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.11518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:55:03Z","timestamp":1760291703000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.11518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,7,15]]}},"alternative-id":["10.1002\/cncr.11518"],"URL":"https:\/\/doi.org\/10.1002\/cncr.11518","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7,2]]}}}